Vanda Pharmaceuticals Inc. (VNDA) is set to face a pivotal FDA decision on February 21, 2026, for its drug candidate Bysanti.
Bysanti is proposed for the treatment of bipolar I disorder and schizophrenia, two major psychiatric indications with significant unmet needs. This drug candidate (milsaperidone) is an active metabolite of iloperidone, marketed as Fanapt.
Clinical studies have demonstrated bioequivalence between milsaperidone and iloperidone across dosing ranges, supporting its potential as a once-daily oral therapy.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.